UPDATE: Morgan Stanley On Cabaletta Also Notes 'While initial human data isn't available until 2H20, the approach is supported by the strong CAR T efficacy data. Initial disease targets can support >$1B in peak sales'

Do you like seeing these details as to why an analyst recommended a stock? What could we do to make this product better? Let us know by emailing newsdesk@benzinga.com

Benzinga · 11/19/2019 16:15